Results of the randomized, placebo-controlled phase I/IIB trial of CV9104, an mRNA based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC)

Autores: Stenzl, A.; Feyerabend, S. ; Syndikus, I.; Sarosiek, T.; Kuebler, H.; Heidenreich, A.; Cathomas, R. ; Grullich, C.; Loriot, Y.; Pérez Gracia, José Luis; Gillessen, S.; Klinkhardt, U.; Schroder, A.; Schonborn-Kellenberger, O.; Reus, V.; Koch, S. D.; Hong, H. S.; Seibel, T.; Fizazi, K.; Gnad-Vogt, U.